Phase 3: Rapid Relief in Thyroid Eye Disease With Veligrotug
Veligrotug, a monoclonal antibody, has shown promising results in treating moderate-to-severe thyroid eye disease. In a phase 3 trial, patients experienced significant improvements in proptosis and diplopia after receiving the treatment. The study indicates that veligrotug may offer a new therapeutic option for managing this condition.
- ▪Veligrotug was administered as five intravenous infusions over 12 weeks to patients with moderate-to-severe active thyroid eye disease.
- ▪At week 15, 70% of patients treated with veligrotug showed a reduction in proptosis compared to only 5% in the placebo group.
- ▪The treatment was generally well tolerated, with a low discontinuation rate and no serious treatment-related adverse events.
Opening excerpt (first ~120 words) tap to expand
TOPLINE:Veligrotug, a full antagonist monoclonal antibody targeting the insulin-like growth factor‑1 receptor, administered as five intravenous (IV) infusions over 12 weeks, demonstrated rapid and durable improvements in proptosis, diplopia, and disease activity in patients with moderate-to-severe active thyroid eye disease (TED). Most patients who had reduced proptosis at week 15 maintained that improvement through week 52. METHODOLOGY:Researchers conducted THRIVE, a global, multicenter, phase 3 trial across 29 sites in North America, Europe, and Australia to evaluate the efficacy and safety of veligrotug in patients with moderate-to-severe active TED.A total of 113 adult patients with moderate-to-severe active TED — with disease onset within 15 months, proptosis at least 3 mm above…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Medscape.
Discussion
0 commentsMore from Medscape
